Science

Inflammation is not the enemy. A stuck alarm is.

Inflammation

When a splinter goes into a finger, the skin around it reddens, swells and hurts. That is inflammation doing its job.

Cells of the innate immune system detect that something is wrong, release signalling molecules, and summon help. Within a few days the splinter is dealt with, the signal stops, and the finger returns to normal.

Alarm panel

A fire alarm with three parts.

The system that raises that alarm is a protein machine called an inflammasome. Think of it as a fire alarm panel with three parts. A sensor notices that something is wrong. An adaptor passes the message on. An effector sounds the alarm by converting a dormant inflammatory signal into its active form and releasing it.

DangersignalsImmune cellNLRP3sensorASCadaptorcaspase-1effectornucleuspro-inflammatorycytokinesDELMUNE · siRNA stops all three parts from being madecarried inside the cell by our lipopolymerApprovedmedicines
Inside an immune cell, a danger signal switches on a sensor (NLRP3), an adaptor (ASC) and an effector (caspase-1). Delmune is designed to act on all three; approved biologics act only on what comes out.
Stuck alarm

In some people the panel never resets.

A small number of people are born with a change in the sensor gene that leaves it too easily triggered. The alarm fires without a fire. The resulting conditions are grouped under the name cryopyrin-associated periodic syndromes, and they include familial cold autoinflammatory syndrome and Muckle-Wells syndrome. They bring recurring fever, rashes that look like hives, joint pain, and in the severest forms, damage to hearing and to the kidneys.

The same alarm panel, firing in the wrong place or for too long, also appears in gout, where it responds to crystals in a joint, and in the cytokine storm that can follow a severe infection.

Silencing

Why silencing beats blocking.

The approved medicines for these conditions all work downstream. They intercept the inflammatory signal after the cell has made and released it. It is an effective strategy and it has changed lives. It is also a strategy that has to be repeated for life, because the panel keeps producing the signal and the drug keeps catching it.

A short interfering RNA works differently. Rather than catching the product, it instructs the cell to stop making the parts. Deliver a sequence matched to the message and the cell degrades that message before a protein is ever built.

The sensor is not blocked. It is not there.

Upstream

Three routes, and what each leaves behind.

Capture the signalafter the cell has released itThe factory keeps running. Dosing continues for life.instructionthe blueprintproteinthe machinesignalthe alarmOccupy the proteinonce it has already been builtThe protein is still made. Coverage has to be unbroken.instructionthe blueprintproteinthe machinesignalthe alarmDelmuneRemove the instructionbefore any of it existsNothing is left to capture and nothing is left to occupy.instructionthe blueprintproteinthe machinesignalthe alarm
Only the third route stops the parts being made at all. It requires the instruction to be intercepted inside an immune cell, which is the delivery problem our lipopolymer was built to solve.

Data

What we measured, and how.

In mice, a single intravenous dose of siRNA in our lipopolymer was measured directly in tissue one day later, with five animals per group. In human cells, immune cells separated from the blood of fifteen healthy volunteers were treated outside the body, and the release of the inflammatory signal was measured.

05001,0001,5002,0002,5003,0003,500picomolar siRNA per 10 ng total RNALung3,266Spleen1,943Bone marrow1,452Liver8234×more siRNA reaches the lungthan reaches the liverThe liver is where conventionalcarriers, such as lipid nanoparticles,end up. Reversing that pattern isthe point of this platform.
Where the siRNA landed, by organ. (Adv Healthcare Mater 2025;14:e02019)
Inflammatory signalling fellNo clear change9 of 15donors respondedA result this strong would arise by chancein roughly one experiment in a hundred.
Fifteen donors, nine responders. Raising the response rate is the next experiment. (RSC Pharmaceutics 2026)